Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00146913
Status:
UNKNOWN
Last Update Posted:
2007-04-27
First Post:
2005-09-05
Brief Title:
AFR10 - Combination Therapy of Imatinib Mesylate IM Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year
Sponsor:
Hospices Civils de Lyon
Organization:
Hospices Civils de Lyon
Study Overview
Official Title:
A Phase II Study Evaluating the Efficacy and Tolerance of Combination Therapy of Imatinib Mesylate IM -2A Interféron for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year
Status:
UNKNOWN
Status Verified Date:
2007-04
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Sixty of CML patients treated by Imatinib mesylate achieved a major cytogenetic responses CCR at 18 months So 40 of the patients must receive additional treatment In vitro it has been shown that IM and Interféron-alpha have synergic anti-proliferative effect on chromosome Ph cell lines By using Peg-Interféron and IM combination we hope to increase the cytogenetic response of patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None